BD reported Q3 2026 earnings and revenues surpassing estimates with margins declining. The company raised its fiscal year 2026 adjusted EPS outlook. Market commentary highlights segment strength offsetting headwinds ahead of Q3 earnings. BD’s shares crossed above the 200-day moving average in July 2026.

• BD reported Q3 2026 earnings and revenues surpassing estimates, with margins down [N1][N3].
• BD held its Q3 2026 earnings conference call on August 6, 2026 [N4].
• Following Q3 results, BD boosted its fiscal year 2026 adjusted EPS outlook [N5].
• Market analysis discussed whether segment strength could offset headwinds for BD stock before Q3 earnings [N7].
• BD shares crossed above the 200-day moving average in July 2026 [N1].

BD’s business benefits from durable demand for medical supplies, devices, and diagnostics globally, supported by a diversified customer base and geographic footprint. The company’s focus on innovation in smart devices, robotics, analytics, and AI aligns with healthcare trends toward improved outcomes and cost efficiencies. Recent financial results show revenue growth and profitability, with Q3 2026 earnings and revenues surpassing expectations and an upward revision to fiscal year 2026 adjusted EPS outlook. The strategic combination of its Biosciences and Diagnostic Solutions business with Waters Corporation could unlock operational and financial synergies. BD’s strong liquidity position and access to capital markets support ongoing investments and strategic initiatives.

BD faces risks from regulatory compliance including FDA clearances and evolving EU medical device regulations, which require significant expenditures and may delay product approvals. The company’s indebtedness and associated covenants impose operational constraints and refinancing risks. Execution risks exist related to the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, including potential disruptions and failure to realize expected benefits. Market dynamics such as volume-based procurement programs, reductions in governmental research funding, and lower vaccine demand have adversely impacted results. Supply chain disruptions, manufacturing interruptions, and intellectual property challenges also pose risks to business continuity and competitive position.

BD’s moat is supported by its broad and diversified portfolio of medical technology products spanning multiple healthcare segments and geographies. The company’s extensive intellectual property portfolio, including patents and proprietary know-how, provides competitive barriers. Its global scale enables distribution through multiple channels and direct customer relationships, reducing customer concentration risk. BD’s ongoing investments in innovation, including in smart devices, robotics, analytics, and AI, aim to maintain category leadership and expand its product pipeline. Regulatory clearances and compliance with complex medical device regulations create additional barriers to entry for competitors. The company’s strategic partnerships and acquisitions further enhance its market position. However, risks remain from patent expirations, regulatory changes, and competitive pressures.

• Regulatory Compliance Risks: BD must comply with FDA requirements and evolving EU Medical Device and In Vitro Diagnostic Regulations, which impose stricter standards and significant costs. Delays or failures in compliance could adversely impact product approvals and market access [S1].
• Indebtedness and Financial Covenants: BD’s substantial debt and associated covenants may restrict operational flexibility. Failure to comply with covenants could lead to default and acceleration of repayment obligations, impacting financial condition [S1].
• Strategic Transaction Risks: The combination of BD’s Biosciences and Diagnostic Solutions business with Waters Corporation carries risks including potential delays, operational disruptions, additional costs, and failure to realize anticipated benefits [S1].
• Market and Operational Risks: Market dynamics such as volume-based procurement programs, reduced research funding, and lower vaccine demand have negatively affected results. Supply chain disruptions and manufacturing interruptions could impair product availability and customer relationships [S1].
• Intellectual Property Risks: Patent expirations, legal challenges, and competition may erode BD’s competitive advantages. Protection of trade secrets and proprietary know-how is subject to risks including breaches and independent development by competitors [S1].

• Becton Dickinson & Co (BD) is a global medical technology company developing, manufacturing, and selling medical supplies, devices, laboratory equipment, and diagnostic products worldwide [S1].
• BD operates through five distinct, separately-managed segments as of October 1, 2025: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences [S1].
• Life Sciences segment includes Specimen Management, Diagnostic Solutions, and Biosciences units, serving hospitals, laboratories, clinics, blood banks, healthcare workers, physicians’ offices, academic and government institutions, and pharmaceutical and biotechnology companies [S1].
• Interventional segment provides vascular, urology, oncology, and surgical specialty products, including disposable and implantable devices, serving hospitals, ambulatory surgery centers, healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business [S1].
• BD’s products are marketed globally through independent distribution channels and direct sales by BD and independent sales representatives [S1].
• No single customer accounted for 10% or more of revenues in the last three years [S1].
• BD reorganized its segments effective October 1, 2025, aligning with product and service offerings [S1].
• BD’s strategy focuses on three pillars: grow, simplify, and empower, emphasizing innovation in smart devices, robotics, analytics, and AI to improve healthcare outcomes and reduce costs [S1].
• BD faces regulatory challenges including FDA clearances and compliance with EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), which impose stricter requirements and significant expenditures [S1].
• BD is subject to complex privacy and data protection laws globally, with risks related to cloud infrastructure, AI, and data processing by third parties [S1].
• BD’s operations depend on patents, trademarks, trade secrets, and proprietary know-how, with risks from patent expirations, legal challenges, and competition [S1].
• BD has significant indebtedness with covenants and restrictions that may affect operations; failure to comply could lead to default and acceleration of repayment obligations [S1].
• BD is in the process of combining its Biosciences and Diagnostic Solutions business with Waters Corporation, with associated risks including transaction completion, operational disruptions, and realization of expected benefits [S1].
• BD completed the spin-off of its Diabetes Care business (Embecta Corp.) in April 2022 [S1].
• As of June 30, 2026, BD reported cash and cash equivalents of $708 million, current assets of $8.139 billion, current liabilities of $9.404 billion, resulting in a current ratio of 0.87 and a cash ratio of 0.08 [S2].
• For the quarter ended June 30, 2026, BD reported revenues of $4.983 billion, net income of $377 million, and basic and diluted EPS of $1.37 [S2].
• BD’s liquidity ratios as of June 30, 2026, indicate current liabilities exceed current assets, with limited cash coverage [S2].
• BD’s fiscal year 2025 revenues were $21.84 billion, with operating income of $2.579 billion and net income of $1.678 billion [S1].
• BD’s revenues are geographically diversified with approximately $12.79 billion from the United States and $9.05 billion internationally in fiscal 2025 [S1].
• BD’s capital expenditures in fiscal 2025 totaled $760 million, with depreciation and amortization of $2.462 billion [S1].
• BD’s recent Q3 2026 earnings and revenues surpassed estimates, with margins declining [N1][N3].
• BD raised its fiscal year 2026 adjusted EPS outlook following Q3 results [N5].
• BD’s Q3 2026 earnings conference call was held on August 6, 2026 [N4].
• Market commentary discusses BD’s segment strength offsetting headwinds ahead of Q3 earnings [N7].
• BD’s shares crossed above the 200-day moving average in July 2026 [N1].